作者: Helga Rübsamen-Schaeff

支持
Helga Rübsamen-Schaeff, Ph D, is founding CEO of Ai Curis and the chair of Ai Curis” Scientific Advisory Board. Before founding Ai Curis she served at Bayer as SVP and Head of Infectious Disease Research. Before that time, she was Scientific and Managing Director of the Georg-Speyer-Haus in Frankfurt. A chemist by training, Professor Rübsamen-Schaeff has been professor of biochemistry at the University of Frankfurt since 1988. Her research interests focus on research and development of antiviral drugs, novel resistance-breaking antibiotics, emerging infectious diseases and oncology. Prevymis, a drug against HCMV discovered under her direction has reached the market. Helmut Buschmann, Ph D, has over 25 years of international experience in drug discovery research and drug development in the pharmaceutical/biotechnology sectors in different therapeutic areas, from pain research to anti-infectives. Currently, he is Head of Chemistry, Pharmaceutical Development and Patent Affairs at Ai Curis and cofounder and co-owner of RD&C Research, Development & Consulting in Vienna.




2 电子书 Helga Rübsamen-Schaeff

Helga Rübsamen-Schaeff & Helmut Buschmann: New Drug Development for Known and Emerging Viruses
Discusses how to fight Ebola, SARS Corona, and other known or emerging human viruses by building on the successes in antiviral therapy of the past decades Written by leading medicinal chemists and vi …
EPUB
英语
DRM
€171.99
Helga Rübsamen-Schaeff & Helmut Buschmann: New Drug Development for Known and Emerging Viruses
Discusses how to fight Ebola, SARS Corona, and other known or emerging human viruses by building on the successes in antiviral therapy of the past decades Written by leading medicinal chemists and vi …
PDF
英语
DRM
€171.99